Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 1
2011 1
2014 2
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants.
Hammitt LL, Dagan R, Yuan Y, Baca Cots M, Bosheva M, Madhi SA, Muller WJ, Zar HJ, Brooks D, Grenham A, Wählby Hamrén U, Mankad VS, Ren P, Takas T, Abram ME, Leach A, Griffin MP, Villafana T; MELODY Study Group. Hammitt LL, et al. N Engl J Med. 2022 Mar 3;386(9):837-846. doi: 10.1056/NEJMoa2110275. N Engl J Med. 2022. PMID: 35235726 Clinical Trial.
Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity.
Domachowske J, Madhi SA, Simões EAF, Atanasova V, Cabañas F, Furuno K, Garcia-Garcia ML, Grantina I, Nguyen KA, Brooks D, Chang Y, Leach A, Takas T, Yuan Y, Griffin MP, Mankad VS, Villafana T; MEDLEY Study Group. Domachowske J, et al. N Engl J Med. 2022 Mar 3;386(9):892-894. doi: 10.1056/NEJMc2112186. N Engl J Med. 2022. PMID: 35235733 Clinical Trial. No abstract available.
Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants.
Muller WJ, Madhi SA, Seoane Nuñez B, Baca Cots M, Bosheva M, Dagan R, Hammitt LL, Llapur CJ, Novoa JM, Saez Llorens X, Grenham A, Kelly EJ, Mankad VS, Shroff M, Takas T, Leach A, Villafana T; MELODY Study Group. Muller WJ, et al. N Engl J Med. 2023 Apr 20;388(16):1533-1534. doi: 10.1056/NEJMc2214773. Epub 2023 Apr 5. N Engl J Med. 2023. PMID: 37018470 No abstract available.
A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease.
Feltes TF, Sondheimer HM, Tulloh RM, Harris BS, Jensen KM, Losonsky GA, Griffin MP; Motavizumab Cardiac Study Group. Feltes TF, et al. Pediatr Res. 2011 Aug;70(2):186-91. doi: 10.1203/PDR.0b013e318220a553. Pediatr Res. 2011. PMID: 21522037 Clinical Trial.
[Rengalin, a novel drug for treatment of cough in children. Intermediate data on multicentre, comparative randomized clinical trial].
Geppe NA, Kondyurina EG, Galustyan AN, Pak TE, Baltserovich NB, Zhiglinskaya OV, Kamaev AV, Lazareva SG, Laleko SL, Melnikova IM, Mikhalkova EV, Perminova OA, Sabitov AU, Spivakovsky YM. Geppe NA, et al. Among authors: baltserovich nb. Antibiot Khimioter. 2014;59(7-8):16-24. Antibiot Khimioter. 2014. PMID: 25975103 Clinical Trial. Russian.
[Ergoferon liquid dosage form--efficacious and safe treatment for childhood acute respiratory infections. Interim outcomes of a multi-center, randomized, double-blind, placebo-controlled clinical trial].
Geppe NA, Kondiurina EG, Galustian AN, Pak TE, Bal'tserovich NB, Zhiglinskaia OV, Kamaev AV, Lazareva SG, Laléko SL, Mel'nikova IM, Perminova OA, Sabitov AU. Geppe NA, et al. Antibiot Khimioter. 2014;59(5-6):6-14. Antibiot Khimioter. 2014. PMID: 25552038 Clinical Trial. Russian.